Literature DB >> 11719164

Propofol (Diprivan-EDTA) counteracts oxidative injury and deterioration of the arterial oxygen tension during experimental septic shock.

S Basu1, D K Mutschler, A O Larsson, R Kiiski, A Nordgren, M B Eriksson.   

Abstract

PURPOSE: Human septic shock can be replicated in the endotoxaemic pig. Endotoxaemia causes a multitude of events, including reduced PaO(2) and increased lipid peroxidation. This study was designed to evaluate the possible effects of a commonly used anaesthetic drug with known antioxidant properties (propofol) during porcine endotoxaemia.
METHODS: Ten pigs were anaesthetised and given a 6 h E. coli endotoxin infusion. The animals received, randomly, a supplementary continuous infusion of propofol emulsion (containing 0.005% EDTA) or the corresponding volume of vehicle (controls). Pathophysiologic responses were determined. Non-enzymatic (by measuring plasma 8-iso-PGF(2 alpha) and enzymatic (by measuring plasma 15-keto-dihydro-PGF(2 alpha)) lipid peroxidations were evaluated. Plasma levels of the endogenous antioxidants alpha- and gamma-tocopherols, were also analysed.
RESULTS: Endotoxaemia increased plasma levels of 8-iso-PGF(2 alpha) (1st-4th h) and 15-keto-dihydro-PGF(2 alpha) (1st-4th h) significantly more in controls than in the propofol+endotoxin group. PaO(2) was significantly less affected by endotoxin in the propofol treated animals (2nd-4th h). Mean arterial pressure (4th-6th h) and systemic vascular resistance (6th h) were reduced significantly more by endotoxin among the propofol-treated animals. Vitamin E (alpha-tocopherol) increased in all animals, significantly more in the propofol+endotoxin group (1/2-6th h) than in the control group.
CONCLUSIONS: Propofol reduced endotoxin-induced free radical mediated and cyclooxygenase catalysed lipid peroxidation significantly. The implication is that propofol counteracts endotoxin-induced deterioration of PaO(2).

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11719164     DOI: 10.1016/s0300-9572(01)00351-3

Source DB:  PubMed          Journal:  Resuscitation        ISSN: 0300-9572            Impact factor:   5.262


  8 in total

Review 1.  Prostanoid signaling: dual role for prostaglandin E2 in neurotoxicity.

Authors:  Dejan Milatovic; Thomas J Montine; Michael Aschner
Journal:  Neurotoxicology       Date:  2011-03-03       Impact factor: 4.294

2.  Biomarkers of oxidative stress study VI. Endogenous plasma antioxidants fail as useful biomarkers of endotoxin-induced oxidative stress.

Authors:  Maria B Kadiiska; Shyamal Peddada; Ronald A Herbert; Samar Basu; Kenneth Hensley; Dean P Jones; Gary E Hatch; Ronald P Mason
Journal:  Free Radic Biol Med       Date:  2015-01-19       Impact factor: 7.376

3.  Therapeutic effect of propofol in the treatment of endotoxin-induced shock in rats.

Authors:  Ju Gao; Bangxiong Zeng; Luojing Zhou; Shiying Yuan; Shihai Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2003

4.  Concerns of the anesthesiologist: anesthetic induction in severe sepsis or septic shock patients.

Authors:  Seok Hwa Yoon
Journal:  Korean J Anesthesiol       Date:  2012-07-24

5.  Propofol elicits autophagy via endoplasmic reticulum stress and calcium exchange in C2C12 myoblast cell line.

Authors:  Xi Chen; Long-Yun Li; Jin-Lan Jiang; Kai Li; Zhen-Bo Su; Fu-Qiang Zhang; Wen-Jing Zhang; Guo-Qing Zhao
Journal:  PLoS One       Date:  2018-05-24       Impact factor: 3.240

Review 6.  Polyphenols: Bioavailability, Microbiome Interactions and Cellular Effects on Health in Humans and Animals.

Authors:  Michael B Scott; Amy K Styring; James S O McCullagh
Journal:  Pathogens       Date:  2022-07-05

7.  Effects of propofol on endotoxin-induced acute lung injury in rabbit.

Authors:  Sang Hyun Kwak; Jeong Il Choi; Jong Tae Park
Journal:  J Korean Med Sci       Date:  2004-02       Impact factor: 2.153

8.  Comparison of cardiovascular response to laryngoscopy and tracheal intubation after induction of anesthesia by Propofol and Etomidate.

Authors:  Mehrdad Masoudifar; Elham Beheshtian
Journal:  J Res Med Sci       Date:  2013-10       Impact factor: 1.852

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.